Science 37

What Science 37 does

Science 37 is a US-based clinical research site organization that operates a Direct-to-Patient (DTP) clinical trial site model, enabling study visits to be conducted in patients' homes rather than at traditional brick-and-mortar investigator sites. The company's core platform provides 50-state medical licensure, research-grade nursing (150+ W-2 nurses certified in GCP, HSR, and IATA), centralized IRB submission under a single Form FDA 1572, investigational medicinal product shipment from a central pharmacy (via Catalent), and real-time data access for sponsors. It operates as the first and only FDA-inspected Direct-to-Patient clinical trial site, having passed three consecutive inspections with No Action Indicated classifications and zero Form 483 observations across five Phase 3 trials. Complementary service lines include a Patient Recruitment offering built on a proprietary 6 million+ patient database with medical record-qualified referrals (results-based, 90%+ outcomes-driven pricing) and a recently launched Pediatrics Department with specialized investigators and nurses.

The company sells primarily to pharmaceutical sponsors, biotech firms, and contract research organizations through an enterprise field sales motion, with clinical trial agreements as the revenue mechanism. Customers include GSK, Bayer, Boehringer Ingelheim, Biohaven, Jazz Pharmaceuticals, Mirum, Anthos, and other large pharma counterparties, with case-study outcomes showing 20-30% of total study enrollment contributed as a single site and 86% completion rates versus the roughly 36% benchmark at traditional sites. Founded in 2012, the company went public via SPAC in 2021 (Nasdaq: SNCE) and was acquired by eMed LLC in March 2024 for $5.75 per share through a tender offer, returning to private ownership. Under eMed, it continues to operate as a subsidiary focused on decentralized trial execution, having supported over 200 clinical trials and delivered 14,000+ in-home visits across all 50 US states.

Science 37's technology stack integrates the patient recruitment database, nationwide nursing workforce scheduling and logistics, central IRB and compliance infrastructure (via Advarra), laboratory services (via LabConnect), and telehealth/telemedicine interfaces to coordinate remote study visits. The platform supports decentralized, hybrid, and fully at-home trial designs across Phase I-IV and observational studies, with documented results in therapeutic areas including primary biliary cholangitis, narcolepsy, asthma, vascular Ehlers-Danlos syndrome, COVID-19, colorectal cancer, and Fragile X. Peer-reviewed validation comes from a Tufts Center for the Study of Drug Development landmark study, and the company has been recognized repeatedly by Frost & Sullivan, Everest Group, MedTech Breakthrough, and Gartner as a leader in decentralized clinical trials.

Name

Science 37

Legal name

Science 37 Holdings Inc.

Website

http://science37.com

Company type

Private

Founded year

2014

Operating status

Acquired

Headcount range

501–1,000 employees

Short description

Science 37 is a US clinical research site organization that runs Direct-to-Patient clinical trials in patients' homes, serving pharmaceutical and biotech sponsors with FDA-inspected site services, nationwide research-grade nursing, and medical record-qualified patient recruitment across all 50 states.

Ownership category

akta.pro rank

Product category

Decentralized Clinical Trial Site Services

NAICS

Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (6215)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Trial Site Operations & Study Coordination (HLAGACAE)

akta.pro secondary industry

Clinical Trial Monitoring Support (On-site/Remote) (HLAGACAG)

Keywords

• Decentralized clinical trials
• Direct-to-patient site
• Patient recruitment services
• Research-grade nursing
• Pediatric clinical research

Headquarters

HQ city

Culver City

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Direct-to-Patient Site Services: Science 37 generates revenue by providing clinical trial site services directly to pharmaceutical companies, biotechs, and CROs. As a site organization, they conduct study visits in patients' homes, deliver research-grade nursing, manage patient recruitment, and provide investigator oversight. Revenue is earned through clinical trial agreements with sponsors for enrollment and site services.
2. Patient Recruitment Services: Results-based patient enrollment services providing medical record-qualified referrals to sponsors and sites. Pricing model is 90%+ results-driven to minimize sponsor risk.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Science 37 operates an FDA-inspected Direct-to-Patient (DTP) Clinical Trial Site that enables sponsors to run clinical trials in patients' homes across all 50 US states. Its offerings include the DTP Site platform (50-state licensure, single IRB/1572, research-grade nursing, IMP shipment, home-visit execution), medical-record-qualified Patient Recruitment (6M+ patient database, results-based pricing), a nationwide Research-Grade Nursing Network (150+ GCP/HSR/IATA-certified nurses), and a dedicated Pediatrics Department for pediatric and rare-disease studies. Customers are pharmaceutical companies, biotechs, and CROs conducting Phases I-IV and observational studies.

Product overview

Science 37 is an industry-leading patient access company that operates as a single Direct-to-Patient Site platform, augmented by complementary service offerings. The core Direct-to-Patient Site enables clinical trials to be conducted directly in patients' homes with FDA-inspected quality, supported by 50-state medical licensure. This platform is complemented by Patient Recruitment services (medical record-qualified referrals), Research-Grade Nursing (in-home nurse deployments), and specialized Pediatric Research capabilities. Together, these offerings enable sponsors to expand access beyond traditional brick-and-mortar site constraints, improve patient diversity, and accelerate enrollment timelines.

Differentiator

Problem solved

Functional benefit

Products and services

• Direct-to-Patient Site The FDA-inspected Direct-to-Patient Clinical Trial Site enables sponsors to conduct study visits in patients' homes across all 50 US states. Features include 50-state medical licensure by board-certified investigators, a single Form FDA 1572, central IRB submission, IMP shipment from central pharmacy, kit and study supplies delivery, and nationwide coordination of research-grade nurses — allowing sponsors to reach 100% of target patient populations beyond traditional site catchments. Three consecutive FDA inspections have resulted in No Action Indicated (NAI) classifications.
• Patient Recruitment Results-based patient recruitment delivering medical-record-qualified, site-ready referrals. Uses a proprietary database of 6 million+ patients combined with heatmapping technology, omni-channel outreach, and clinician-reviewed eligibility to deliver pre-screened study-qualified participants. Pricing is 90%+ results-driven to minimize sponsor risk and accelerate randomization.
• Research-Grade Nursing A nationwide network of 150+ research-grade nurses (Science 37 employees) trained and certified in GCP, HSR, and IATA who conduct in-home study visits across all 50 US states. Nurses deliver protocol-specific clinical assessments, laboratory services, IMP handling, and data capture, achieving 100% visit completion across 15,500+ nurse deployments.
• Pediatric Research Direct-to-patient clinical research delivery model designed for children, adolescents, and their families, supporting Phase I-III and observational pediatric trials across multiple therapeutic areas. Backed by a dedicated Pediatrics Department with specialized leadership, board-certified pediatric investigators (including Pediatrics and Internal Medicine), and pediatric-trained research nurses and clinical research coordinators, designed to reduce family burden while maintaining regulatory compliance and high retention (94% retention reported in difficult-to-retain pediatric rare disease populations).

Quantifiable outcome

• 86% completion rate vs ~36% in traditional sites
• +11 more outcomes

Named customers15 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• CatalentcoreStrategic or Co-development PartnerScience 37 and Catalent announced a partnership enabling universal access to clinical research. Catalent provides direct-to-patient pharmacy operations including IMP shipment and supply chain logistics. Science 37 provides Direct-to-Patient Site services including research-grade nursing and investigator oversight. Joint panel sessions at ARCP events discuss direct-to-patient and decentralized delivery.
• RxE2coreStrategic or Co-development PartnerScience 37 partnered with RxE2 on the 'Pharm-to-Trial' program, a decentralized vaccine trial model bringing research to agricultural U.S. communities by utilizing local pharmacies as trusted access points. This hub-and-spoke model removes socioeconomic barriers and leverages local healthcare relationships to improve diversity and data quality.
• GSKcoreStrategic or Co-development PartnerScience 37 partnered with GSK on a Phase 3 rare disease trial for cholestatic pruritus in primary biliary cholangitis (PBC). Science 37 contributed 47% of U.S. enrollment and achieved 82.3% completion rate. GSK emphasized Science 37's ability to bring trials to patients' homes in rural areas.
• Tufts CSDDcoreStrategic or Co-development PartnerScience 37 collaborated with Tufts Center for the Study of Drug Development on a landmark study publishing performance data on Direct-to-Patient Clinical Trial Site performance. The peer-reviewed analysis validates Science 37's model against industry benchmarks, demonstrating 86% completion rates and 20-30% enrollment contribution.

Scale indicators15 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Medable: A leading decentralized clinical trial (DCT) technology platform serving pharma and biotech sponsors with eCOA, eConsent, and remote patient data capture. Medable is the most direct technology peer to Science 37's Direct-to-Patient Site, competing for the same DCT sponsor wallet.
• ObvioHealth: A DCT-focused CRO operating its own site-less, direct-to-patient model for Phase I–IV trials. Closely comparable to Science 37 on delivery model, sponsor target, and therapeutic-area breadth.
• Curebase: A decentralized clinical trial software and site-services provider that runs fully virtual and hybrid trials. Competes with Science 37 for sponsors seeking patient-centric, in-home trial execution.
• Signant Health: Provider of patient-centric clinical trial technology and eCOA/pro endpoints solutions, including decentralized and hybrid trial capabilities. Overlaps with Science 37 in DCT delivery and sponsor relationships.
• Thread (now part of Verily): A decentralized clinical trial platform and services company (acquired by Verily) supporting fully remote and hybrid studies. Directly comparable to Science 37 on DCT operating model and sponsor customers.

Broad incumbents

• IQVIA: The largest global CRO and clinical research services provider, with growing decentralized trial capabilities embedded in its broad portfolio. Competes with Science 37 on Phase 3 site work while offering a much wider, fully integrated service suite.
• ICON plc: A top-tier global CRO (post-PRA Health Sciences) with established DCT and hybrid trial offerings. Comparable as a large-scale site-and-trial-services competitor to Science 37's decentralized model.
• Fortrea (formerly Labcorp Drug Development): A global CRO spun out from Labcorp, providing Phase I–IV clinical development and central lab services including decentralized trial offerings. Competes with Science 37 for sponsor Phase 3 site work.
• Medidata (Dassault Systèmes): A leading clinical trial technology platform (Rave, eCOA, decentralized trial suite) owned by Dassault Systèmes. Comparable as a technology-and-services enabler of DCT and hybrid trial execution.

Emerging players

• Clinical Ink: A DCT-focused eCOA, ePRO, and direct-to-patient data capture provider supporting hybrid and decentralized trials. A more narrowly focused emerging competitor to Science 37's Direct-to-Patient Site on patient-centric data capture.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/science-37
• Xx.com/science37x
• Facebookfacebook.com/science37

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds6 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Science 37